Placental growth factor as a new marker for predicting abnormal glucose challenge test results

被引:5
作者
Cengiz, Huseyin [1 ]
Kaya, Cihan [1 ]
Ekin, Murat [1 ]
Yesil, Ali [1 ]
Dagdeviren, Hediye [1 ]
机构
[1] Bakirkoy Dr Sadi Konuk Teaching & Res Hosp, Dept Obstet & Gynecol, Istanbul, Turkey
关键词
Diabetes; insulin; pregnancy; GESTATIONAL DIABETES-MELLITUS; HYPERGLYCEMIA; PREGNANCY; HORMONE; TOLERANCE; GH;
D O I
10.3109/09513590.2013.813477
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: To differentiate placental growth factor (PlGF) levels in pregnancies with normal and abnormal glucose challenge test (GCT) results. Methods: A total of 94 pregnant women underwent a 50 -g GCT as part of our routine antenatal screening protocol from September 2011 to January 2012. The patients were divided into three groups: (i) normal GCT, (ii) abnormal GCT and (iii) gestational diabetes mellitus (GDM) based on the screening results for gestational diabetes. The main outcome measure of the study was the relationship between PlGF and GCT results in non-diabetic pregnancies. The Kolmogorov-Smirnov test was used to check the normality of the variables' distributions. The Kruskal-Wallis and analysis of variance tests (Tukey's test) were used to analyze the qualitative parameters. Results: There were 53 (56.4%), 22 (23.4%) and 19 (20.2%) patients in the normal GCT, abnormal GCT and GDM groups, respectively. The PlGF level in the abnormal GCT group was 518 +/- 307.6 pg/mL, which was the highest level in the study population, and there was a statistically significant difference compared with the other groups (p = 0.006). There were no statistically significant differences with respect to fetal birth weight among the three groups in our study. Conclusion: PlGF can be used as a laboratory marker to predict which patients will have abnormal GCT results.
引用
收藏
页码:909 / 911
页数:3
相关论文
共 18 条
  • [1] Amer Diabet Assoc, 2006, DIABETES CARE, V29, pS43
  • [2] Gestational diabetes mellitus
    Buchanan, TA
    Xiang, AH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (03) : 485 - 491
  • [3] Human placental growth hormone, insulin-like growth factor I and -II, and insulin requirements during pregnancy in type 1 diabetes
    Fuglsang, J
    Lauszus, F
    Flyvbjerg, A
    Ovesen, P
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) : 4355 - 4361
  • [4] Gavin JR, 2000, DIABETES CARE, V23, pS4
  • [5] Maternal and Fetal Placental Growth Hormone and IGF Axis in Type 1 Diabetic Pregnancy
    Higgins, Mary F.
    Russell, Noirin E.
    Crossey, Paul A.
    Nyhan, Kristine C.
    Brazil, Derek P.
    McAuliffe, Fionnuala M.
    [J]. PLOS ONE, 2012, 7 (02):
  • [6] Screening for gestational diabetes mellitus: A systematic review for the US preventive services task force
    Hillier, Teresa A.
    Vesco, Kimberly K.
    Pedula, Kathryn L.
    Beil, Tracy L.
    Whitlock, Evelyn P.
    Pettitt, David J.
    [J]. ANNALS OF INTERNAL MEDICINE, 2008, 148 (10) : 766 - U93
  • [7] Proposed diagnostic thresholds for gestational diabetes mellitus according to a 75-g oral glucose tolerance test. Maternal and perinatal outcomes in 3260 Danish women
    Jensen, DM
    Damm, P
    Sorensen, B
    Molsted-Pedersen, L
    Westergaard, JG
    Korsholm, L
    Ovesen, P
    Beck-Nielsen, H
    [J]. DIABETIC MEDICINE, 2003, 20 (01) : 51 - 57
  • [8] Placental growth hormone (GH), GH-binding protein, and insulin-like growth factor axis in normal, growth-retarded, and diabetic pregnancies: Correlations with fetal growth
    McIntyre, HD
    Serek, R
    Crane, DI
    Veveris-Lowe, T
    Parry, A
    Johnson, S
    Leung, KC
    Ho, KKY
    Bougoussa, M
    Hennen, G
    Igout, A
    Chan, FY
    Cowley, D
    Cotterill, A
    Barnard, R
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03) : 1143 - 1150
  • [9] McIntyre HD, 2002, HORM METAB RES, V34, P250
  • [10] Metzger BE, 2008, NEW ENGL J MED, V358, P1991, DOI 10.1056/NEJMoa0707943